Related Experiment Video
Updated: Mar 29, 2026
07:35
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
8.1K
Subgroup identification for treatment selection in biomarker adaptive design
Tzu-Pin Lu1,2, James J Chen3,4
1Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, Food and Drug Administration, 3900 NCTR Road, HFT-20, Jefferson, AR, 72079, USA. tplu@ntu.edu.tw.
BMC Medical Research Methodology
|December 10, 2015
Summary
Diagonal Linear Discriminant Analysis (DLDA) improves patient subgroup identification for targeted therapies. This method enhances treatment efficacy and statistical testing accuracy in adaptive clinical trial designs.
Area of Science:
- Biostatistics
- Clinical Trial Design
- Translational Medicine
Background:
- Molecular advancements drive targeted drug development for specific patient subgroups.
- Adaptive Signature Design (ASD) aims to optimize treatment efficacy by identifying suitable patient cohorts.
- Effective biomarker-adaptive designs require accurate patient classification and robust statistical testing for treatment effects.
Purpose of the Study:
- To propose and evaluate a classification method for identifying patient subgroups.
- To present a statistical testing strategy for detecting treatment effects in identified subgroups.
- To compare the proposed method against the existing ASD classification approach.
Main Methods:
- Diagonal Linear Discriminant Analysis (DLDA) was employed for subgroup classification.
- A two-step procedure was used for continuous endpoints, involving model fitting and cutoff determination.
- The strategy included tests for treatment effects in all patients, marker-positive, and marker-negative subgroups.
Main Results:
- The DLDA classifier demonstrated high accuracy, sensitivity, specificity, and predictive values.
- DLDA outperformed the ASD method in accuracy on simulated and cancer datasets.
- The subgroup testing strategy proved effective in detecting treatment effects and controlling errors.
Conclusions:
- Classifier accuracy is critical for the success of adaptive trial designs.
- Inaccurate classifiers can lead to misallocated treatments and reduced statistical power.
- The proposed DLDA-based procedure offers an effective approach for subgroup identification and analysis in adaptive designs.
Related Concept Videos
01:20Comparing the Survival Analysis of Two or More Groups
704
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
704
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
529
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
529
01:15Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
386
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
386
01:20Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
368
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
368
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
68
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
01:29Pharmacogenomics: Identification of New Drug Targets
76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76